Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00274326 · ClinicalTrials.gov registry record · Phase 3

DILIPO (DILutIonal HyPOnatremia)

A Phase 3 study of Congestive Heart Failure, sponsored by Sanofi.

Completed
Registry status
Phase 3
Development phase
150
Enrollment target
15
Study locations

NCT00274326 is a Phase 3 study of Congestive Heart Failure that has completed, run by Sanofi. The registered enrollment target is 150 participants, below the 327-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (54% lower). The trial reports 15 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00274326, a Phase 3 study of Congestive Heart Failure, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 3
Development phase
150 participants
Enrollment target
15
Study locations

Study Summary

Primary: * To assess the efficacy of SR121463B in correcting hyponatremia in patients with dilutional hyponatremia other than SIADH or cirrhosis Secondary: * To assess the long-term efficacy of SR121463B in maintaining normonatremia in these patients * To assess the safety and tolerability of SR121463B

Conditions Studied

Congestive Heart Failure

Interventions

  • DRUG SR121463B

Study Locations (15)

Other

  • Sanofi-Aventis Administrative Office - Buenos Aires
  • Sanofi-Aventis Administrative Office - Diegem
  • Sanofi-Aventis Administrative Office - Laval
  • Sanofi-Aventis Administrative Office - Santiago
  • Sanofi-Aventis Administrative Office - Hørsholm
  • Sanofi-Aventis Administrative Office - Athens
  • Sanofi-Aventis Administrative Office - Budapest
  • Sanofi-Aventis Administrative Office - Netanya
  • Sanofi-Aventis Administrative Office - Warsaw
  • Sanofi-Aventis Administrative Office - Porto Salvo
  • Sanofi-Aventis Administrative Office - Bucharest
  • Sanofi-Aventis Administrative Office - Midrand
  • Sanofi-Aventis Administrative Office - Bromma

New Jersey

  • Sanofi-Aventis Administrative Office - Bridgewater

New South Wales

  • sanofi-aventis Australia & New Zealand administrative office - Macquarie Park

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2005-05
Est. Completion 2007-07
Phase Phase 3

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00274326

The ClinicalTrials.gov registry entry for NCT00274326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (54% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which SR121463B is the first listed.

NCT00274326 reports 15 study locations spanning 3 distinct geographic areas - top geographies include Other, New Jersey, New South Wales.

Frequently Asked Questions

What is clinical trial NCT00274326 about?

NCT00274326 is a clinical study titled "DILIPO (DILutIonal HyPOnatremia)". Primary: * To assess the efficacy of SR121463B in correcting hyponatremia in patients with dilutional hyponatremia other than SIADH or cirrhosis Secondary: * To assess the long-term efficacy of SR121463B in maintaining normonatremia in these patients * To assess the safety and tolerability of SR1...

What is the current status of trial NCT00274326?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2005-05. Estimated completion is 2007-07.

What conditions does trial NCT00274326 study?

This clinical trial studies the following conditions: Congestive Heart Failure.

What interventions are being tested in trial NCT00274326?

The interventions under investigation include: SR121463B (DRUG).

Who is sponsoring clinical trial NCT00274326?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00274326 being conducted?

This trial has 15 study locations across New Jersey, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Congestive Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Congestive Heart Failure

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.